ArticleBritish journal of cancer2004
Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy.
Article in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.Epidemiologic reviews · 2014Pooled it
- The 2020 Menopausal Hormone Therapy Guidelines.Journal of menopausal medicine · 2020Review
- Long-term exposure to road traffic noise and incidence of breast cancer: a cohort study.Breast cancer research : BCR · 2018Article
- Article
- Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients.Geburtshilfe und Frauenheilkunde · 2015Article
- Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin.Medical oncology (Northwood, London, England) · 2013Article
- Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use.Medical oncology (Northwood, London, England) · 2012Article
- Breast tumor characteristics in hormone replacement therapy users.Pathology oncology research : POR · 2011Article
- The relationship between hormone therapy use at the time of diagnosis of breast cancer and tumor characteristics.Hormones & cancer · 2010Article
- Recent declines in breast cancer incidence: mounting evidence that reduced use of menopausal hormones is largely responsible.Breast cancer research : BCR · 2010Article
- Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2008Article
- Prediagnostic use of hormone therapy and mortality after breast cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2008Article
- Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008Article
- Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study.Breast cancer research : BCR · 2008Article
- Relationship between epidemiologic risk factors and breast cancer recurrence.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2007Article
- Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study.Breast cancer research : BCR · 2006Article
- Therapy for menopausal symptoms during and after treatment for breast cancer : safety considerations.Drug safety · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to investigate the risk of developing prognostic different types of breast cancer in women using hormone replacement therapy (HRT). A total of 10 874 postmenopausal Danish Nurses were followed since 1993. Incident breast cancer cases and histopathological information were retrieved through the National Danish registries. The follow-up ended on 31 December 1999. Breast cancer developed in 244 women, of whom 172 were invasive ductal carcinomas. Compared to never users, current users of HRT had an increased risk of a hormone receptor-positive breast cancer, but a neutral risk of receptor-negative breast cancer, relative risk (RR) 3.29 (95% confidence interval (CI): 2.27-4.77) and RR 0.99 (95% CI: 0.42-2.36), respectively (P for difference=0.013). The risk of being diagnosed with low histological malignancy grade was higher than high malignancy grade with RR 4.13 (95% CI: 2.43-7.01) and RR 2.17 (95% CI: 1.42-3.30), respectively (P=0.063). For breast cancers with other prognostic characteristics, the risk was increased equally for the favourable and non favourable types. Current users of HRT experience a two- to four-fold increased risk of breast cancer with various prognostic characteristics, both the favourable and non favourable types. For receptor status, the risk with HRT was statistically significantly higher for hormone receptor-positive breast cancer compared to receptor-negative breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.